Background: INFLAMMATORY MEDIATORS are an important component in the pathophysiology of the coronavirus disease 2019 (COVID-19). This study aimed to assess the effects of reducing INFLAMMATORY MEDIATORS using hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the mortality of patients with COVID-19. Materials and Methods: Twelve patients with confirmed diagnosis of COVID19 were included. All patients had acute respiratory distress syndrome (ARDS). Patients were divided into three groups, namely, HP, CRRT and HP+CRRT. The primary outcome was mortality and the secondary outcomes were oxygenation and reduction in INFLAMMATORY MEDIATORS at the end of the study. Results: Patients were not different at baseline in demographics, INFLAMMATORY cytokine levels, and the level of acute phase reactants. Half of the patients (3 out of 6) in the HP+CRRT group survived along with the survival of one patient (1 out of 2) in the HP group. All four patients in the CRRT group died. Serum creatinine (SCr), Interleukin-1 (IL1), Interleukin-6 (IL6), Interleukin-8 (IL8), partial pressure of oxygen (PaO2), O2 saturation (O2 sat), and hemodynamic parameters improved over time in HP+CRRT and CRRT groups, but no significant difference was observed in the HP group (All Ps > 0. 05). Conclusion: Combined HP and CRRT demonstrated the best result in terms of mortality, reduction of INFLAMMATORY MEDIATORS and oxygenation. Further investigations are needed to explore the role of HP+CRRT in COVID-19 patients.